(Q33194233)

23 July 2017

title

Effect of valspodar on the pharmacokinetics of unbound paclitaxel (English)

1 reference

23 July 2017

1 reference

1 reference

https://api.crossref.org/works/10.1023/A:1025412509730

25 March 2024

1 reference

https://api.crossref.org/works/10.1023/A:1025412509730

25 March 2024

1 reference

6

Alex Sparreboom

1 reference

23 July 2017

4

Jaap Verweij

1 reference

23 July 2017

2

Timothy W. Synold

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14578679

25 March 2024

author name string

Darcy Spicer

series ordinal

3

1 reference

23 July 2017

Albert J. ten Tije

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14578679

25 March 2024

James H. Doroshow

series ordinal

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14578679

25 March 2024

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=14578679

25 March 2024

publication date

1 August 2003

1 reference

Investigational New Drugs

23 July 2017

published in

1 reference

23 July 2017

volume

21

1 reference

23 July 2017

issue

3

1 reference

23 July 2017

page(s)

291-298

1 reference

Phase I study of paclitaxel in combination with a multidrug resistance modulator, PSC 833 (Valspodar), in refractory malignancies.

23 July 2017

cites work

1 reference

12 December 2020

Pharmacokinetic modeling of paclitaxel encapsulation in Cremophor EL micelles

1 reference

12 December 2020

Altered clearance of unbound paclitaxel in elderly patients with metastatic breast cancer

1 reference

12 December 2020

A phase I trial of doxorubicin, paclitaxel, and valspodar (PSC 833), a modulator of multidrug resistance

1 reference

12 December 2020

Paclitaxel pharmacokinetics and pharmacodynamics

1 reference

12 December 2020

Mechanism-based pharmacokinetic model for paclitaxel

1 reference

12 December 2020

Linearized colorimetric assay for cremophor EL: application to pharmacokinetics after 1-hour paclitaxel infusions.

1 reference

12 December 2020

Comparative pharmacokinetics of unbound paclitaxel during 1- and 3-hour infusions

1 reference

12 December 2020

Selective biotransformation of taxol to 6 alpha-hydroxytaxol by human cytochrome P450 2C8

1 reference

12 December 2020

A general model for time-dissociated pharmacokinetic-pharmacodynamic relationship exemplified by paclitaxel myelosuppression

1 reference

12 December 2020

Determination of paclitaxel in human plasma using single solvent extraction prior to isocratic reversed-phase high-performance liquid chromatography with ultraviolet detection.

1 reference

12 December 2020

Role of intestinal P-glycoprotein in the plasma and fecal disposition of docetaxel in humans.

1 reference

12 December 2020

Phase I dose-finding and pharmacokinetic study of paclitaxel and carboplatin with oral valspodar in patients with advanced solid tumors

1 reference

12 December 2020

Does P-glycoprotein play a role in anticancer drug pharmacokinetics?

1 reference

12 December 2020

Disposition of Cremophor EL in humans limits the potential for modulation of the multidrug resistance phenotype in vivo

1 reference

12 December 2020

Effect of high-dose cyclosporine on etoposide pharmacodynamics in a trial to reverse P-glycoprotein (MDR1 gene) mediated drug resistance

1 reference

12 December 2020

Inter-relationships of paclitaxel disposition, infusion duration and cremophor EL kinetics in cancer patients

1 reference

12 December 2020

The orally administered P-glycoprotein inhibitor R101933 does not alter the plasma pharmacokinetics of docetaxel.

1 reference

12 December 2020

Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine

1 reference

12 December 2020

Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans

1 reference

12 December 2020

Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation

1 reference

12 December 2020

Role of formulation vehicles in taxane pharmacology

1 reference

12 December 2020

Quantitation of Cremophor EL in human plasma samples using a colorimetric dye-binding microassay

1 reference

12 December 2020

A dose-finding and pharmacokinetic study of reversal of multidrug resistance with SDZ PSC 833 in combination with doxorubicin in patients with solid tumors.

1 reference

12 December 2020

Phase I study of etoposide with SDZ PSC 833 as a modulator of multidrug resistance in patients with cancer

1 reference

12 December 2020

Measurement of fraction unbound paclitaxel in human plasma.

1 reference

12 December 2020

Identification of P450 enzymes involved in metabolism of verapamil in humans

1 reference

12 December 2020

In vivo circumvention of P-glycoprotein-mediated multidrug resistance of tumor cells with SDZ PSC 833

1 reference

12 December 2020

P-Glycoprotein inhibitor valspodar (PSC 833) increases the intracellular concentrations of daunorubicin in vivo in patients with P-glycoprotein-positive acute myeloid leukemia

1 reference

12 December 2020

The P-glycoprotein antagonist PSC 833 increases the plasma concentrations of 6alpha-hydroxypaclitaxel, a major metabolite of paclitaxel.

1 reference

12 December 2020

Subpopulations of normal peripheral blood and bone marrow cells express a functional multidrug resistant phenotype

1 reference

12 December 2020

Metabolism of taxol by human hepatic microsomes and liver slices: participation of cytochrome P450 3A4 and an unknown P450 enzyme

1 reference

12 December 2020

Nonlinear pharmacokinetics of paclitaxel in mice results from the pharmaceutical vehicle Cremophor EL

1 reference

12 December 2020

Multidrug resistance in cancer: role of ATP-dependent transporters

1 reference

12 December 2020

The multidrug resistance modulator valspodar (PSC 833) is metabolized by human cytochrome P450 3A. Implications for drug-drug interactions and pharmacological activity of the main metabolite

1 reference

12 December 2020

Cremophor EL-mediated alteration of paclitaxel distribution in human blood: clinical pharmacokinetic implications.

1 reference

12 December 2020

Cyclosporine metabolism in human liver: identification of a cytochrome P-450III gene family as the major cyclosporine-metabolizing enzyme explains interactions of cyclosporine with other drugs.

1 reference

12 December 2020

Development of multidrug-resistance convertors: sense or nonsense?

1 reference

12 December 2020

Restoration of taxol sensitivity of multidrug-resistant cells by the cyclosporine SDZ PSC 833 and the cyclopeptolide SDZ 280-446

1 reference

12 December 2020

Indirect-response model for the time course of leukopenia with anticancer drugs.

1 reference

12 December 2020

Phase I study of infusional paclitaxel in combination with the P-glycoprotein antagonist PSC 833.

1 reference

12 December 2020

Drug Metabolism and Disposition

6

26

802

V Fischer

1998

1 reference

Crossref

DOI

https://api.crossref.org/works/10.1023/A:1025412509730

Drug Metabolism and Disposition

25 March 2024

12

28

1141

E Brouwer

2000

1 reference

Crossref

DOI

https://api.crossref.org/works/10.1023/A:1025412509730

25 March 2024

Identifiers

DOI

1 reference

Dimensions Publication ID

23 July 2017

1017655721

0 references

1 reference